| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloid-Derived Suppressor Cells | 4 | 2021 | 100 | 2.190 |
Why?
|
| Killer Cells, Natural | 18 | 2023 | 904 | 2.110 |
Why?
|
| Interleukin-12 | 10 | 2021 | 253 | 0.810 |
Why?
|
| Interferon-gamma | 11 | 2017 | 1144 | 0.730 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 166 | 0.570 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 2864 | 0.530 |
Why?
|
| Lymphocyte Activation | 5 | 2017 | 1688 | 0.510 |
Why?
|
| T-Lymphocytes | 5 | 2021 | 3869 | 0.500 |
Why?
|
| Neoplasms | 8 | 2023 | 15193 | 0.490 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1870 | 0.410 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2023 | 1763 | 0.410 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2019 | 56 | 0.320 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 243 | 0.300 |
Why?
|
| Receptors, Fc | 3 | 2017 | 69 | 0.240 |
Why?
|
| Chemokines | 3 | 2019 | 314 | 0.230 |
Why?
|
| Neuroblastoma | 2 | 2019 | 686 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.210 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 60 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 7 | 2017 | 4367 | 0.200 |
Why?
|
| Cytokines | 3 | 2005 | 2809 | 0.200 |
Why?
|
| K562 Cells | 2 | 2019 | 338 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2021 | 204 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2020 | 269 | 0.160 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2019 | 675 | 0.160 |
Why?
|
| Trastuzumab | 7 | 2017 | 696 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 280 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2020 | 251 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 1555 | 0.150 |
Why?
|
| Interleukin-7 | 1 | 2017 | 95 | 0.150 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2008 | 12 | 0.150 |
Why?
|
| Receptors, IgG | 2 | 2008 | 102 | 0.140 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2017 | 235 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2019 | 1146 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 3821 | 0.140 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 14551 | 0.140 |
Why?
|
| Ligands | 1 | 2019 | 995 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2004 | 2295 | 0.130 |
Why?
|
| Adenoviridae | 1 | 2021 | 1459 | 0.130 |
Why?
|
| Humans | 24 | 2023 | 261506 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 475 | 0.120 |
Why?
|
| Animals | 15 | 2021 | 59536 | 0.120 |
Why?
|
| Mice | 14 | 2021 | 34495 | 0.120 |
Why?
|
| Antineoplastic Agents | 7 | 2011 | 14289 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2518 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 598 | 0.110 |
Why?
|
| Immunoglobulin G | 4 | 2015 | 1021 | 0.100 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2011 | 84 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 1724 | 0.090 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 2 | 2005 | 11 | 0.090 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 2 | 2005 | 13 | 0.090 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 15694 | 0.080 |
Why?
|
| Cancer Vaccines | 2 | 2004 | 697 | 0.080 |
Why?
|
| CD56 Antigen | 2 | 2004 | 83 | 0.080 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 80 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 2 | 2006 | 259 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 259 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1859 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2017 | 1797 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2011 | 3251 | 0.070 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2005 | 84 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2008 | 1764 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 657 | 0.070 |
Why?
|
| Receptors, Interleukin | 1 | 2005 | 97 | 0.070 |
Why?
|
| Monokines | 1 | 2004 | 15 | 0.070 |
Why?
|
| CD3 Complex | 2 | 2004 | 314 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 5 | 2011 | 2314 | 0.060 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2004 | 34 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2005 | 709 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 261 | 0.060 |
Why?
|
| Female | 13 | 2021 | 141928 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2006 | 1538 | 0.060 |
Why?
|
| Chemokine CCL4 | 1 | 2004 | 63 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 3719 | 0.060 |
Why?
|
| Interleukins | 1 | 2006 | 325 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 5 | 2005 | 6942 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5061 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 460 | 0.060 |
Why?
|
| Flow Cytometry | 3 | 2004 | 3033 | 0.060 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2003 | 32 | 0.060 |
Why?
|
| CpG Islands | 1 | 2005 | 633 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 2005 | 889 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 1390 | 0.050 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 4821 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2005 | 4804 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 5112 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 4938 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2004 | 478 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2004 | 2232 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 862 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 1489 | 0.050 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 62 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2004 | 673 | 0.050 |
Why?
|
| Transfection | 1 | 2005 | 2944 | 0.050 |
Why?
|
| Escherichia coli Infections | 1 | 2002 | 241 | 0.050 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 7789 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2003 | 1555 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2021 | 626 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 3 | 2005 | 156 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 1450 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 3639 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2003 | 1271 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 1248 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 176 | 0.040 |
Why?
|
| Sepsis | 1 | 2002 | 652 | 0.040 |
Why?
|
| Feeder Cells | 1 | 2016 | 13 | 0.030 |
Why?
|
| Time Factors | 3 | 2005 | 12926 | 0.030 |
Why?
|
| Genotype | 1 | 2004 | 4109 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2016 | 85 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2005 | 5710 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 2016 | 121 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2006 | 15862 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1987 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1022 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 7226 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 788 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7222 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2006 | 1519 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2004 | 9244 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2005 | 5637 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 677 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.020 |
Why?
|
| Spleen | 2 | 2003 | 676 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 2004 | 842 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 703 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 2508 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2005 | 32848 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2008 | 10 | 0.020 |
Why?
|
| Syk Kinase | 1 | 2008 | 56 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2017 | 11965 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 301 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 334 | 0.020 |
Why?
|
| Cell Line | 2 | 2004 | 5114 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2006 | 157 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 5395 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2006 | 138 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 734 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2005 | 78 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 2004 | 23 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2004 | 97 | 0.020 |
Why?
|
| L-Selectin | 1 | 2004 | 34 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2003 | 4143 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 182 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 2738 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 2450 | 0.020 |
Why?
|
| Aged | 3 | 2005 | 70117 | 0.020 |
Why?
|
| Male | 3 | 2021 | 123000 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 658 | 0.020 |
Why?
|
| Adult | 3 | 2005 | 77950 | 0.010 |
Why?
|
| Measles virus | 1 | 2003 | 15 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 634 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 2003 | 39 | 0.010 |
Why?
|
| Chromium | 1 | 2002 | 14 | 0.010 |
Why?
|
| Middle Aged | 3 | 2005 | 86204 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 582 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 149 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2005 | 446 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 604 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 239 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 332 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2002 | 115 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 4053 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2003 | 336 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2003 | 266 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 197 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2004 | 368 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2002 | 221 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 1265 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 957 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 886 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8873 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 1678 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 461 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1165 | 0.010 |
Why?
|
| Etoposide | 1 | 2002 | 870 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2054 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 716 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 1756 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 2927 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 2074 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 999 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 1869 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 2489 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 1586 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 2466 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 891 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 4233 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 3472 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 6089 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2002 | 1549 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 3001 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2002 | 3005 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 4757 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 7548 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 12221 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 29902 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 11538 | 0.000 |
Why?
|